SAMe (S-adenosyl-L-methionine)
Also called: S-adenosylmethionine, S-adenosyl-L-methionine, ademetionine, SAM-e
S-adenosyl-L-methionine is a chemical the body makes from the amino acid methionine; it helps regulate key functions in living cells. In the US it is sold as a dietary supplement; in Europe it is called ademetionine.
- Category
- Amino acid and protein
- Forms
- S-adenosylmethionine, including forms stabilized as salts (e.g. 1,4-butanedisulfonate, disulfate tosylate) named in FDA's NDI list
- Strongest evidence
- B Some positive trials
- Reviewed
- 2026-10-30
Class 1 Well studied in people. An AHRQ evidence report meta-analyzed 28 randomized trials of SAMe for depression (versus placebo or conventional antidepressants) and 10 for osteoarthritis (versus placebo or NSAIDs). It does not state routes; NCCIH says some studies used injected SAMe, and a 2016 Cochrane review included oral and parenteral trials. [2]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BBrain, mood and sleep2 topics
CLiver1 topic
CBones and joints1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Depression in adults | B | A 2016 Cochrane review (8 RCTs, 934 adults; oral or parenteral SAMe) found no strong evidence of a difference from placebo alone, results similar to imipramine, and one trial (73 participants) favoring SAMe as an SSRI add-on. Evidence quality: low to very low. [3] |
| Depression: SAMe alone or added to antidepressants | C | A 2024 meta-analysis (14 trials, 1,522 subjects; 200-3,200 mg/day for 2-12 weeks) found no significant difference from placebo, imipramine or escitalopram; the authors urge caution given few studies. [4] |
| Osteoarthritis of the knee or hip | C | A 2009 Cochrane review (4 placebo-controlled trials, 656 patients) found a small, non-significant pain difference (0.4 cm on a 10 cm scale), called the evidence inconclusive and advised against routine use. [5] |
| Liver disease | C | NCCIH states benefit in people is not established; for intrahepatic cholestasis of pregnancy, studies conflicted and data are insufficient, and research on other liver conditions is inconclusive. [1] |
Main constituents: S-adenosyl-L-methionine, made in the body from methionine [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Depression trials in a 2024 meta-analysis used 200 to 3,200 mg/day of SAMe for 2 to 12 weeks. [4]
- In liver studies in a 2024 systematic review, the most common doses were 1,000 mg or 1,200 mg per day. [6]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingSAMe has been used for cholestasis during pregnancy, but its safety in pregnancy has not been established …
1 statement in the profile.
Details and sources - Interactions with medicines2 listed
Levodopa (L-dopa); Antidepressants and other serotonin-raising drugs
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications11 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- SAMe may worsen mania; NCCIH says people with bipolar disorder should not take it for depressive symptoms unless a health care provider supervises. [1]
- The 2016 Cochrane review recorded two reports of mania/hypomania among 441 participants in the SAMe arms. [3]
- Side effects are uncommon and usually minor, such as nausea or digestive upset; long-term safety data are limited because most studies were short. [1]
- Theoretically, SAMe could promote Pneumocystis carinii infection in immunocompromised people such as those with HIV, because it may enhance the organism's growth. [1]
- It has been used for cholestasis during pregnancy, but its safety in pregnancy has not been established. [1]
Interactions
| With | What happens |
|---|---|
| Levodopa (L-dopa) | SAMe may reduce the effects of levodopa, used for Parkinson's disease. [1] |
| Antidepressants, L-tryptophan, St. John's wort | SAMe may interact with drugs and supplements that raise serotonin levels. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- FDA's NDI list includes notifications for SAMe stabilized with 1,4-butanedisulfonate or disulfate tosylate, and disulfate tosylate with propyl gallate. [7]
Regulatory status
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- S-adenosyl-L-methionine (SAMe), made in the body from the amino acid methionine Amino acids, amines and peptides (methionine derivative) [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 11 entries naming S-adenosylmethionine, SAMe or ademetionine, including stabilized salt forms (earliest NDI 22 submitted 1997-10-21; most recent NDI 1376 submitted 2024-12-12). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of S-adenosylmethionine was found (IARC Monographs list of classifications, Volumes 1–142, and NTP technical reports checked 2026-10-30). [P3]
- The NTP Technical Reports index (TR-001 to TR-606) lists no study of S-adenosylmethionine (checked 2026-10-30). [P4]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- St. John's wort; L-tryptophan: May interact with these serotonin-raising supplements. [P1]
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P5]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- SAMe has been used for cholestasis during pregnancy, but its safety in pregnancy has not been established; NCCIH advises consulting a provider if pregnant or nursing. [P1]
Sources for this profile
- NCCIH. S-Adenosyl-L-Methionine (SAMe): In Depth (last updated January 2017), 2017-01. nccih.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142, 2026-10-30. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-30. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/29/2026), 2026-10-29. ecfr.gov
Sources
- NCCIH. S-Adenosyl-L-Methionine (SAMe): In Depth (last updated January 2017), 2017-01. nccih.nih.gov
- Hardy ML, Coulter I, Morton SC, et al. S-Adenosyl-L-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease: Summary. AHRQ Evidence Report/Technology Assessment No. 64 (AHRQ Pub. No. 02-E033, August 2002; NCBI Bookshelf page current as of August 2003, provided for historical reference), 2003-08. ncbi.nlm.nih.gov
- Galizia I, et al. S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database Syst Rev 2016;10:CD011286 (PMID 27727432), 2016-10-10. pubmed.ncbi.nlm.nih.gov
- Peng TR, et al. S-Adenosylmethionine (SAMe) as an adjuvant therapy for patients with depression: an updated systematic review and meta-analysis. Gen Hosp Psychiatry 2024;86:118-126 (PMID 38199136), 2024-01. pubmed.ncbi.nlm.nih.gov
- Rutjes AW, et al. S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009;(4):CD007321 (PMID 19821403), 2009-10-07. pubmed.ncbi.nlm.nih.gov
- Baden KER, et al. S-Adenosylmethionine (SAMe) for Liver Health: A Systematic Review. Nutrients 2024;16(21):3668 (PMID 39519500), 2024-10-28. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in amino acid and protein: 5-HTP (5-hydroxytryptophan) · Beta-alanine · BPC-157 · Branched-chain amino acids (BCAAs) · Carnosine (L-carnosine) · Collagen peptides · Creatine · Glutathione · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.